The invention relates to methods for reducing the level of xenobiotic in an environment by contacting the environment with a composition comprising one or more bacterial strains. The invention also relates to bacterial strains for use in method of reducing the level of xenobiotic in a subject. The invention also relates to compositions comprising one or more bacterial strains.
A61P 39/00 - Agents protecteurs généraux ou antipoisons
C02F 3/00 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p.ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
The present invention provides a method of analysing a sample obtained from a subject having or suspected of having a somatic disease state, the method comprising: (a) providing a tissue, proximal or distal sample of limited quantity, such as a cell-free DNA (cfDNA)-containing sample obtained from the subject and performing methylation sequencing of at least 10 predetermined genomic regions, wherein said methylation sequencing may comprise a non-destructive, enzyme-based conversion method to differentiate unmethylated cytosine from 5-methylcytosine and/or 5- hydroxymethylcytosine; (b) generating metrics from the methylation sequencing reads in step (a) that represent one or both of (i) a measure of the degree to which the methylation observed within a sequencing read is similar to a previously determined disease methylation signal, said measure comprising a read rating generated by providing a vector of methylation states for each methylation sequencing read and summing the information content of all methylation states that are concordant with the methylation state for the same region previously determined in a one or more disease samples; and (ii) a measure of intra-read methylation heterogeneity; and (c) integrating the metrics generated in step (b) across the at least 10 predetermined genomic regions to obtain a global measure of disease-originating cfDNA in the sample obtained from the subject. Related methods and systems for use in performing the methods are also provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
The invention provides a method for determining the state of charge (SOC) of an electrolyte, such as an electrolyte within a flow battery, by measuring the bulk magnetic susceptibility of the electrolyte. The method includes the step of measuring the magnetic susceptibility of an electrolyte in a measurement region and determining the state of charge of the electrolyte based on the magnetic susceptibility of the electrolyte.
G01R 31/387 - Détermination de la capacité ampère-heure ou de l’état de charge
G01N 27/76 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables magnétiques des fluides par recherche de la susceptibilité
H01M 8/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible à régénération, p.ex. batteries à flux REDOX ou éléments à combustible secondaires
4.
METHOD OF TREATMENT OF MALARIA BY TARGETTING OPEN READING FRAMES
The present application features methods of diagnosing treating malaria by targeting novel open reading frames in Plasmodium falciparum. The novel open reading frames (nORFs) associated with malaria are expressed in a mosquito and in a human
Disclosed herein include methods, compositions, culture media, and devices for in vitro culture of synthetic embryos from mammalian pluripotent stem cells. The in vitro embryo model is generated with embryonic and extraembryonic lineages derived from embryonic stem cells through transcription-factor-mediated reprogramming and can undergo advanced development to late headfold stages.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
6.
Transplantation of Liver Cells by Administration to the Biliary Tree of the Liver
This invention relates to in vitro and in vivo methods for engrafting liver cells, such as cholangiocytes, into a liver comprising administering the liver cells to the biliary tree of the liver. The liver cells may be in the form of aggregates and may be administered in the direction of decreasing biliary duct diameter. This may be useful for example for the treatment of an individual with a diseased or damaged liver.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A formed sheet metal structure is manufactured from a sheet metal workpiece (1, 101). A main anvil tool (10, 110) constrains the first surface (3, 103) of the sheet metal workpiece. The workpiece is bent to form a first basal region (50, 150) and a second basal region (60, 160) with a bend (56, 156) between them. A first auxiliary forming tool (30) deforms first and second sidewall portions (51, 61, 151, 161) with respect to the first and second basal regions (50, 60, 150, 160) thereby to form a first fold region (55, 165) in the sheet metal workpiece (1, 101) between the first sidewall portion (51, 151) and the second sidewall portion (61, 161). Progressively sliding the first auxiliary forming tool (30) along the first fold region (55, 165) causes shear material transfer in the first fold region (55, 165) to further deform the first fold region (55, 165).
B21D 5/01 - Cintrage des tôles le long de lignes droites, p.ex. pour former un pli simple entre des marteaux et des enclumes ou butées
B21D 5/04 - Cintrage des tôles le long de lignes droites, p.ex. pour former un pli simple sur des presses particulières avec fixation d'un côté de la pièce
A housing for sample collection is disclosed. The housing comprises an actuating member configured to move between a first position and a second position, a sample collector and an assay component. In the first position the sample collector is in contact with the assay component and in the second position the sample collector is separated from the assay component and configured to collect a sample.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
A61B 5/151 - Dispositifs de prélèvement d'échantillons de sang spécialement adaptés pour le prélèvement d'échantillons de sang capillaire, p.ex. par des lancettes
B01L 9/00 - Dispositifs de support; Dispositifs de serrage
9.
ABSORPTION INDUCED CALORIC EFFECTS AND USES THEREOF
The present invention relates to use of a fluid to drive a phase transition induced by absorption/desorption of the fluid into and out of the caloric material. A method is providing in which a sorptiocaloric material is contacted with a fluid such that the fluid is absorbed into and at least partially throughout the sorptiocaloric material to induce a phase transition and heat is permitted to flow to or from the sorptiocaloric material. The fluid is then released and is desorbed out of the sorptiocaloric material to induce the reverse phase transition and reverse heat flow. The sorptiocaloric phase transition is capable of very large latent heats under ambient conditions making it potentially useful in conventional cooling and heating applications as well as thermal storage.
F25B 17/08 - Machines, installations ou systèmes à sorption, à marche discontinue, p.ex. à absorption ou à adsorption l'absorbant ou l'adsorbant étant un solide, p.ex. du sel
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
C09K 5/04 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état vapeur ou vice versa
10.
METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS
Disclosed herein include methods, compositions and culture media for generating synthetic embryos in vitro from mammalian pluripotent stem cells such as pluripotent embryonic stem cells. In some embodiments, the method can comprise co-culturing a wild-type mammalian pluripotent stem cell and modified mammalian pluripotent stem cells comprising one or more genes encoding transcription factors that can drive generation of extraembryonic cells or extraembryonic-like cells (e.g., GATA6 gene, SOX17 gene, GATA3 gene and/or TFAP2C gene) under a condition in a culture medium allowing the pluripotent stem cells to self-organize into a post-implantation embryo structure. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells and the generated synthetic embryo is a human embryo.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
An optical element comprising a first wavelength band filter film including a diffractive optical structure, wherein the diffractive optical structure diffracts light including light in a first wavelength band so as to form a first array of optical focal points. The wavelength band filter film selectively performs one of reflecting and transmitting the light in the first wavelength band and selectively performs the other of reflecting and transmitting light outside the first wavelength band.
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
The invention relates to a method of preparing a nucleic acid library from a sample comprising high molecular weight DNA (HMW DNA), preferably genomic DNA, comprising the steps (i) contacting said DNA with a first restriction enzyme and a second restriction enzyme; (ii) contacting said DNA with a pair of oligonucleotide adapters according to any of claims 1 to 12; (iii) contacting said DNA with at least one DNA ligase; and (iv) incubating to allow digestion of the DNA by said first restriction enzyme and second restriction enzyme, annealing of said oligonucleotide adapters to the digested DNA, and ligation of the annealed oligonucleotide adapters to the digested DNA by said at least one DNA ligase. The invention also relates to oligonucleotide adapters, a kit, and uses of same.
LRR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
LRR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
Provided are compounds of the Formula II, and salts, hydrates and solvates thereof: (Formula (II) wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the prodrugs defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: I wherein Q1, R1, Ra, Rb, Rc, Rd, Re, A1 and A2 are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
LRR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
in vitroGATA6SOX17GATA3TFAP2CTFAP2C gene) under a condition in a culture medium allowing the pluripotent stem cells to self-organize into a post-implantation embryo structure. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells and the generated synthetic embryo is a human embryo.
23344, the composition comprising particles comprising sub- particles, the sub-particles having a mean greatest dimension of from 10 to 300nm. Methods of making such a composition are also described.
H01M 4/14 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs au plomb
20.
TREATMENT OF CANCER ASSOCIATED WITH VARIANT NOVEL OPEN READING FRAMES
International Centre for Genetic Engineering and Biotechnology (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a cancer associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant leads to increased or reduced expression of the variant nORF.
International Centre for Genetic Engineering and Biotechnology (Royaume‑Uni)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a cancer associated with a dysregulated novel open reading frame (nORF) in which increased or reduced expression of the dysregulated nORF is associated with cancer.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
The present application relates to metal-organic framework (MOF) nanoparticles, in particular, coated MOF nanoparticles, methods of manufacturing said coated MOF nanoparticles, and uses of said coated MOF nanoparticles.
International Centre for Genetic Engineering and Biotechnology (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a disease associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant encodes either the gain or loss of a stop codon.
The present invention provides an electrode having a substrate and a conductive polymer film layer on the exposed surface, the film layer having a capacitance per area of at least 0.5 F/cm2and/or wherein the film layer has a thickness of between 50-1000 µm. A medical device having a plurality of electrodes wherein at least one of the electrodes includes a polymer film layer, the film layer having a capacitance per area of at least 0.5 F/cm2is also provided, as are systems including the medical device, methods of treatment of a spinal cord lesion and methods of manufacturing the electrodes.
The present invention provides an implantable medical device having: a flexible substrate (10); a delivery conduit (20) formed in the flexible substrate and having an inlet and an outlet located at a proximal end of the device, wherein the delivery conduit passes from the inlet to the outlet via a loop at a distal end of the device; and a delivery hole formed in the delivery conduit allowing passage of fluid from the conduit to the exterior of the substrate. Aspects of the invention also provide a system for the delivery of medicament to a patient and a controller (43) for an implantable medical device which is configured to deliver the medicament predominantly by diffusion rather than convection.
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
The invention relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10), or a bone morphogenetic protein 9 (BMP9) variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease. The invention also relates to novel BMP9 variants and to pharmaceutical compositions comprising said polypeptides.
A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
27.
A LAYERED STRUCTURE COMPRISING A COMPOSITE THIN SINGLE LAYER DEPOSITED OVER A BASE ELECTROLYTE LAYER FOR AN ELECTROCHEMICAL DEVICE, A PROCESS FOR MANUFACTURING AND USES THEREOF
FUNDACIÓ INSTITUT DE RECERCA EN ENERGIA DE CATALUNYA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA ESTUDIS AVANCATS (Espagne)
CAMBRIDGE ENTERPRISE LTD (CE) (Royaume‑Uni)
Inventeur(s)
Tarancón Rubio, Albert
Baiutti, Federico
Torrell Faro, Marc
Bernadet, Lucile
Alayo Bueno, Nerea
Driscoll, Judith
Wells, Matt
Abrégé
The present invention relates to a layered structure comprising a composite thin single layer deposited over a base electrolyte layer for an electrochemical device. The present invention further relates to a process for manufacturing said layered structure and uses thereof.
H01M 8/1246 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte l'électrolyte étant constitué d’oxydes
H01M 8/1253 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte l'électrolyte étant constitué d’oxydes l'électrolyte contenant de l’oxyde de zirconium
H01M 8/126 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte l'électrolyte étant constitué d’oxydes l'électrolyte contenant de l’oxyde de cérium
H01M 8/1213 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par la combinaison électrode/électrolyte ou par le matériau de support
A system is disclosed for scanning a structural object, comprising a mobile scanning device configured to scan the structural object from a plurality of successive locations to generate for each location a respective point cloud representing a respective portion of the structural object; a calculating unit configured to: (i) determine from the point clouds a pose graph comprising estimates of positions of the successive locations in relation to the structural object; and (ii) calculate for each location a respective uncertainty value in the pose graph; and a display configured to display the point clouds and to provide a visual indication for each point cloud of the calculated uncertainty value of the corresponding location in the pose graph.
The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for expressing proteins in plants to promote symbiotic infection. The invention also provides plants and plant cells transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.
This invention relates to mapping the binding sites of a test compound within a nucleic acid. The nucleic acid is contacted with a tagged test compound that binds to the nucleic acid or to protein associated with the nucleic acid at one or more locations. The tagged test compound is contacted with a first binding member that specifically binds to the tag and a second binding member that specifically binds to the first binding member and is attached to an activatable nuclease, such that the second binding member binds to first binding member that is bound to the tagged test compound at the one or more binding sites. The nuclease is then activated to cleave the nucleic acid at the binding sites to generate fragments. The sequence of the generated fragments is indicative of the binding sites of the test compound.
A computer implemented method of predicting liquid-liquid phase separation LLPS) behaviour of a biomolecule, the method comprising: inputting information identifying the biomolecule and its environmental composition and/or chemical modification of the biomolecule to an algorithm configured to predict, whether the biomolecule will exhibit LLPS under specified environmental conditions and/or chemical modification of the biomolecule, wherein: the algorithm is an algorithm generated by machine learning trained on data featurised according to features relating to biomolecules in the training data and features relating to the environmental conditions and/or chemical modification of the biomolecules in the training data, and the algorithm outputs a prediction of whether the biomolecule will exhibit LLPS under the specified environmental conditions and/or chemical modification of the biomolecule.
The invention provides a method for labeling a nucleic acid comprising N6-methyl adenine. The method comprises forming an alpha-amino radical on the N6-methyl group of N6mAde, and capturing the alpha-amino radical with a radical acceptor comprising a nitrosopyridyl group. The presence of N6mAde in a nucleic acid may then be established by detection of the labeled nucleic acid, or the labeled nucleic acid may be extracted or further modified using the label. Also provided is a method for mapping the position of N6mAde within a target nucleic acid, and probe molecules and kits for use in the method.
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p.ex. séquençage par hybridation [SBH]
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p.ex. transfert d’énergie de résonance
C07D 213/61 - Atomes d'halogènes ou radicaux nitro
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p.ex. des carbamates
33.
Composite Layers, Methods for Their Manufacture and Uses Thereof
A composite layer of carbon nanotubes and metal such as copper is formed by electrodeposition. The layer has a thickness of at least 10 μm. The carbon nanotubes are distributed through the layer and are present in the layer at a volume fraction of at least 0.001 vol % and at most 65 vol %. The volume fraction is based on the total volume of the metal and carbon nanotubes and not including any pore volume. The carbon nanotubes are substantially uniformly plated with the metal. The composite layer has a density ratio satisfying Player Pmetal ≤0.35 where player is the bulk density of the composite layer of thickness of at least 10 μm, including any voids that are present in the composite layer and pmetal is the volumetric mass density material property of the metal. The composite layer is of use in evaporation-condensation apparatus, as an active material layer in an electrochemical device or in an electroforming process.
C25D 13/02 - Revêtement électrophorétique caractérisé par le procédé avec des matières inorganiques
F28D 15/04 - Appareils échangeurs de chaleur dans lesquels l'agent intermédiaire de transfert de chaleur en tubes fermés passe dans ou à travers les parois des canalisations dans lesquels l'agent se condense et s'évapore, p.ex. tubes caloporteurs avec des tubes ayant une structure capillaire
A microfluidic sensor comprising: a first substrate; a second substrate; a cavity formed between the first substrate and the second substrate, the cavity comprising a reservoir portion and a channel portion extending from the reservoir portion; a capacitive element disposed between the first substrate and the second substrate, the capacitive element being at least partially disposed in the channel portion of the cavity; and a dielectric sensing liquid provided in the reservoir portion. Upon application of a force to the first substrate adjacent the reservoir portion, the reservoir portion is configured to deform and displace the sensing liquid along the channel portion, so as to change the capacitance of the capacitive element within the channel portion.
A61F 2/46 - Outils particuliers pour l'implantation des articulations artificielles
G01L 1/14 - Mesure des forces ou des contraintes, en général en mesurant les variations de la capacité ou de l'inductance des éléments électriques, p.ex. en mesurant les variations de fréquence des oscillateurs électriques
G01L 1/02 - Mesure des forces ou des contraintes, en général par des moyens hydrauliques ou pneumatiques
B81B 3/00 - Dispositifs comportant des éléments flexibles ou déformables, p.ex. comportant des membranes ou des lamelles élastiques
The invention relates to a modified stem cell-like cell for use in organ regeneration or repair wherein the modified stem cell-like cell exhibits reduced ion flow through sodium leak channel (NALCN). The invention also relates to an ion channel modulator for use in organ regeneration or repair. The invention further relates to associated methods, for example, a method of repairing or regenerating an organ.
A61K 35/36 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées Épiderme; Cellules épithéliales; Kératinocytes; Cellules de Langerhans; Cellules ectodermiques
The present invention relates to a method of spatially barcoding one or more biological molecules located on or within a substrate by using a transposase complex to label the biological molecule of interest with a detection probe which may then give rise to a spatial barcode. Such analysis may include determining the spatial profiling of one or more biological molecules, specifically the spatial analysis of DNA, open chromatin, chromatin features, proteins and/or RNA which may be spatially barcoded by methods of the invention, either alone or in various combinations. The invention further relates to a transposase complex for use in spatially barcoding one or more biological molecules and reagents kits for performing such methods.
An image generation system for providing a ghost image free head-up display, the system comprising a display screen having a front surface and a back surface, a picture generation unit for projecting an image towards the display screen for reflection towards an eye box, a field lens, and an anisotropic optical component having a first optical power along a first axis and second optical power along a second axis, wherein the first and second axis are perpendicular, wherein the picture generation unit is configured to project light through the field lens such that light is incident on the front surface of the display screen forming a first virtual image, wherein a portion of the light is transmitted through the display screen and is incident on the back surface of the display screen forming a second virtual image, wherein the first and second virtual images are offset along the first axis, wherein the field lens is configured to project the first virtual image at a first projection distance and the second virtual image at a second projection distance such that the offset is below a threshold magnitude and the first and second virtual images are substantially overlaid as viewed from the eye box, and wherein the anisotropic optical component is configured to magnify the first and second virtual image along the second axis only.
The invention relates to methods for modulating the symbiotic relationship between plants, for example legumes, and nitrogen fixing bacteria in the root nodules. The invention also relates to modified plants, for example gene edited plants that have an altered symbiotic relationship with nitrogen fixing bacteria in the root nodules.
22, -OH and -SH, and the protected forms of each, -W- is optionally substituted methylene, such as methylene, and d is a double or single bond, and the salts and solvates thereof
C07C 233/33 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons doubles avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminée; Leurs dérivés
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A radio/microwave frequency current probe comprising one or more resistive elements electrically connected between a current input region and a current output region, and a stack of layers each comprising a dielectric material. For each of the resistive elements, the current probe further comprises a plurality of conductive paths each separated by one or more of the layers. A first set of the conductive paths are configured to provide a current path between the current input region and the resistive element, while a second set of conductive paths are configured to provide a current path between the resistive element and the current output region. The plurality of conductive paths are arranged such that the first and second sets of conductive paths alternate in the stack of layers. The current probe may also be integrated into current measurement systems.
G01R 1/20 - Modifications des éléments électriques fondamentaux en vue de leur utilisation dans des appareils de mesures électriques; Combinaisons structurelles de ces éléments avec ces appareils
The invention relates to methods of identifying enzymes and methods of screening for optimised enzymes for degrading polymers such as plastics. The invention also relates to polymer degrading enzymes and nucleic acids encoding these enzymes as well as expression cassettes and host cells comprising the nucleic acids. The invention also relates to uses of these enzymes or the host cells comprising the nucleic acids encoding these enzymes to degrade polymers such as plastics. Lastly, the invention also relates to the crystal structure of plastic degrading enzymes and uses of these structures.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
42.
PROTEINS FOR REGULATION OF SYMBIOTIC NODULE ORGAN IDENTITY
The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for expressing proteins in plants to promote symbiotic infection. The invention also provides plants and plant cells transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.
The present invention concerns methods of diagnosing and/or prognostication of non-alcoholic fatty liver disease (NAFLD) or alcohol-related fatty liver disease (ARLD) in a subject, wherein said methods comprise detecting somatic mutations in DNA, RNA and/or protein that confer a selective advantage on one or more liver cells of the subject. The present invention also provides methods for identifying subjects suffering from NAFLD or ARLD who would benefit from treatment with a therapeutic agent and/or identifying subjects suffering from NAFLD or ARLD who would benefit from increased disease monitoring. The present invention also provides therapeutic agents that find utility in the treatment of NAFLD or ARLD.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
44.
ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES
Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to nucleophosmin 1 located on the surface of cells, as well as antibody-drug conjugates (ADCs) comprising such antibodies. Also provided herein are methods of treating cancers in which NPM1 is expressed on the surface of cancer cells, by administering to a subject an NPM1-binding antibody or antibody conjugate described herein and a chemotherapeutic drug.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
45.
MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE
Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to wild-type and/or mutant nucleophosmin 1 located on the surface of cells. These antibodies, as well as antibody conjugates comprising these antibodies, are useful for the detection and treatment of cancers in which NPM1 is expressed on the surface of cancer cells.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to plant-based microcapsules for the efficient encapsulation and retention of water-soluble ingredients, as well as the efficient co-encapsulation of water-soluble and water-insoluble ingredients. The present invention also relates to compositions comprising the microcapsules, a method of making the microcapsules and compositions, and to uses of the microcapsules and compositions.
A23D 7/005 - Compositions à base d'huiles ou de graisses comestibles, contenant une phase aqueuse, p.ex. margarines caractérisées par des ingrédients autres que des triglycérides d'acides gras
The invention provides a ternary complex of a cucurbituril host, such as CB[8], with a first aryl guest and second aryl guest, wherein the first aryl guest is a group within a biomolecule, such as insulin, and the first and second aryl guests are diferent. Also provided is a method of decomplexing the complex, the method comprising the step of treating the complex with a competitor guest, and permiting the competitor guest to displace at least the first aryl guest from the complex.
C07K 1/113 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs sans changement de la structure primaire
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The disclosure provides a PKC inhibitor and a cytotoxic agent for use in therapy, wherein the PKC inhibitor reaches a peak concentration in a subject prior to the cytotoxic agent reaching a peak concentration. The PKC inhibitor and the cytotoxic 5 agent may be used to treat cancer or an autoimmune disease.
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p.ex. benzimidazoles
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p.ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p.ex. sulfadiazine
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
49.
MAT2A INHIBITOR AND/OR TSG101 INHIBITOR FOR USE IN ANTIVIRAL THERAPY
The invention relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infection in a subject. More specifically, the invention relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infections caused by DNA viruses or nuclear replicating viruses. The invention also relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infections caused by RNA viruses.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/20 - Antiviraux pour le traitement des virus ADN
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
The present invention relates to polydopamine co-polymer nanoparticles as defined in the application. The present invention also relates to processes for the preparation of these polydopamine co-polymer nanoparticles, to pharmaceutical compositions comprising them, and to their use in therapy.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
The invention provides an engineered immune cell, wherein the engineered immune cell comprises a gain-of-function mutation in a Cav channel and/or overexpresses an L-type voltage-gated calcium (Cav) channel. Also provided are related engineered immune cells for use in medicine. Also provided are L-type Cav channel agonists for use in a method of stimulating cell killing activity of an immune cell in a subject having a proliferative disorder. Pharmaceutical compositions and methods are also provided.
The invention relates to microfluidic methods; and modular devices and systems for implementing the methods. The invention also relates to uses of these devices and systems for biological analyses.
Broadly speaking, embodiments of the present techniques provide a method, apparatus and system for automatically detecting and correcting errors in manufacturing parameters of a manufacturing process using closed-loop control. Advantageously, the present techniques not only monitor manufacturing parameters but also provide instructions to enable any unacceptable variation in a manufacturing parameter to be corrected during the manufacturing process.
G05B 13/02 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
G05B 19/4099 - Usinage de surface ou de courbe, fabrication d'objets en trois dimensions 3D, p.ex. fabrication assistée par ordinateur
The present invention relates to adeno-associated virus (AAV) capsid proteins that have been modified to insert an amino acid sequence and/or methods of targeting microglia or brain macrophages using the AAV capsid proteins of the invention.
112341x1234xx are defined herein. The present invention also relates to compositions comprising the compounds of formula (I) or formula (X) defined herein, to processes for synthesising these compounds and to their use for the treatment and/or detection of diseases and conditions in which coagulation proteases, in particular APC, flla, fXa, and fXla, are implicated.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
C07K 5/107 - Tétrapeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p.ex. Phe, Tyr
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p.ex. Lys, Arg
C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p.ex. Pro, His, Trp
A method of characterizing one or more particles in a fluid, e.g. a liquid, using interferometric scattering optical (iSCAT) microscopy. The method involves illuminating a region of a fluid using an objective lens so that light is scattered by one or more particles in the fluid. The scattered light and reference light are captured using the objective lens and interfere at an imaging device. A succession of images of the interference is processed to determine image correlation values which define a gradual decorrelation over time from which a property of the particle(s) is determined.
G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une image; Leurs détails spécifiques
G03H 1/04 - Procédés ou appareils pour produire des hologrammes
57.
MODULAR MICROFLUIDIC DEVICES, SYSTEMS AND METHODS FOR TOTAL RNA ANALYSES
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (Pays‑Bas)
Inventeur(s)
Hollfelder, Florian
Kaminski, Tomasz
De Jonghe, Joachim
Salmen, Fredrik
Van Oudenaarden, Alexander
Abrégé
Modular microfluidic devices, systems and methods for total RNA analyses The invention relates to microfluidic methods of preparing a sequencing library for analyses of total RNA. The invention also relates to modular microfluidic systems for carrying out these methods.
A magnetic particle (30, 70) has a layered structure (6, 56) between a top surface of the particle and an opposed bottom surface of the particle. Layers of the structure include one or more non- magnetic layer(s) and one or more magnetized layer(s). The ratio of a lateral dimension of the one or more magnetized layers to the aggregate thickness of the magnetized layer or layers is greater than 500. A plurality of such magnetic particles (30, 70) can be functionalised and marked with readable codes (16, 66) corresponding to the functionalisation, for use for performing assays such as bioassays.
H01F 10/26 - Pellicules magnétiques minces, p.ex. de structure à un domaine caractérisées par le substrat ou par les couches intermédiaires
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
59.
RESISTIVE SWITCHING DEVICES AND METHODS FOR THEIR MANUFACTURE AND OPERATION
A resistive switching memory device comprises an active layer comprising an ionic conducting material. The active layer is disposed on a substrate. The device further comprises: a first electrode, a second electrode and optionally a first semiconductor layer. One of the first electrode, second electrode and first semiconductor layer, when present, is the substrate for the active layer and wherein the active layer and the first semiconductor layer, when present, contact each other at an interface. The device exhibits hysteretic I-V behaviour to permit switching of the electrical resistance of the device between different resistance states. The active layer is non-epitaxial with respect to the substrate.
H10N 70/00 - Dispositifs à l’état solide sans barrière de potentiel ni de surface, spécialement adaptés au redressement, à l'amplification, à la production d'oscillations ou à la commutation
H10N 70/20 - Dispositifs de commutation multistables, p.ex. memristors
G11C 13/00 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou
The invention provides a method of characterising a DNA sample, the method including the steps of: obtaining a mutational catalogue for the sample, wherein a mutational catalogue comprises counts of mutations in a plurality of predetermined categories; obtaining a mutational signatures catalogue comprising a first set of one or more mutational signatures and a second set of one or more mutational signatures; determining a first set of exposures of the sample to the mutational signatures in the first set of mutational signatures; identifying at least one of the mutational signatures in the second set of mutational signatures that is likely to be present in the sample using the results of the determining; and providing an indication of which of the mutational signatures in the mutational signatures catalogue is present in the sample. Methods of providing a mutational signature catalogue, and related systems and products are also described.
A method of preparing a polyisobutylene-based polyurethane for making heart valves is disclosed, wherein the method includes providing a polyisobutylene (PIB) polymer, freshly distilling a diisocyanate compound to create a freshly distilled diisocyanate and providing a chain extender. When the polyisobutylene polymer, the freshly distilled diisocyanate, and the chain extender are combined together by mixing, the created polyisobutylene-based polyurethane exhibits a higher number average molecular weight, a higher ultimate strength, a higher elongation, and a greater toughness than a polyisobutylene-based polyurethane made without a freshly distilled diisocyanate, which makes the polymer particularly useful as a bioprosthetic heart valve.
C08G 18/64 - Composés macromoléculaires non prévus dans les groupes
C08G 18/76 - Polyisocyanates ou polyisothiocyanates cycliques aromatiques
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
LGR5 binding agents, in particular antibodies or fragments thereof which bind to human LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention provides methods for the non-enzymatic cleavage of target nucleic acids, for example for use in epigenomic and epitranscriptomic mapping and therapy. The method comprises contacting a target nucleic acid molecule with a bifunctional probe comprising a cleavage group and a covalent binding group such that the bifunctional probe covalently binds to the target nucleic acid molecule and cleaves the 5 target nucleic acid molecule bound thereto. Also provided is a method of selectively cleaving a target nucleic acid in a cell, a method for determining the modification of nucleic acid molecules by a nucleic acid modification enzyme in a cell, and a bifunctional probe for use in the methods.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A carrier system (100) provides a carrier or carriers (12) for carrying assay samples in an assay. The carrier(s) are secured to a substrate (10) by a release layer (14). The carrier(s) are suitable for receiving an assay sample, and the release layer is configured to release the carrier(s) from the substrate in the presence of a biocompatible aqueous solution. To perform an assay a biocompatible aqueous solution, in which the assay sample is usually suspended, is supplied to the carrier system. The assay sample is received by the carrier(s) and the release layer is activated by the biocompatible aqueous solution to release the carrier.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A telescope including an optical alignment system. The telescope has a segmented primary mirror and the mirror segments have facets that are used to direct metrology light for aligning the telescope.
G01B 11/27 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour tester l'alignement des axes pour tester l'alignement des axes
G02B 23/02 - Télescopes ou lunettes d'approche, p.ex. jumelles; Périscopes; Instruments pour voir à l'intérieur de corps creux; Viseurs; Pointage optique ou appareils de visée comprenant des prismes ou des miroirs
The present invention relates to a process for preparing a nanoparticle composition comprising cyanine dye nanoparticles. The present invention also relates to said nanoparticles and their uses for detecting senescent cells and determining senescent burden.
This invention relates to an RNA trans- splicing molecule (RTM) that targets human endogenous retrovirus (HERV) pre-mRNA. The RTM comprises (i) a binding region specific for a HERV pre-mRNA, (ii) a trans- splicing splice domain and (ill) a coding sequence for a suicide protein. The binding region of the RTM binds to HERV pre-mRNA in a cell, such that the coding sequence is trans- spliced through the trans- splicing domain with the HERV pre-mRNA, resulting in a chimeric mRNA causing the suicide protein to be expressed in the cell. RTMs of the invention may be useful in selectively killing cells that express HERV genes, for example cancer cells. RTMs, encoding nucleic acids, methods of treatment and associated methods and uses are provided.
Provided are a compound of the formula:
(5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
wherein is a mesogen, and
Rx and Ry are independently selected from hydrogen or substituted or unsubstituted C1-12 alkyl;
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
wherein is a mesogen, and
Rx and Ry are independently selected from hydrogen or substituted or unsubstituted C1-12 alkyl;
The present invention relates to a siloxane-based liquid crystalline elastomer, preferably an exchangeable siloxane-based liquid crystalline elastomer, derived from monomers (A1), (B1) and (C1), wherein (C1) is an acyclic or cyclic vinyl siloxane, and (A1) and (B1) have the following formulae:
wherein is a mesogen, and
Rx and Ry are independently selected from hydrogen or substituted or unsubstituted C1-12 alkyl;
wherein is an organic group.
C08G 77/52 - Composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant du silicium, avec ou sans soufre, azote, oxygène ou carbone dans lesquels au moins deux atomes de silicium, mais pas la totalité, sont liés autrement que par des atomes d'oxygène par des liaisons au carbone contenant des cycles aromatiques
70.
METHOD AND APPARATUS FOR RAPID OPTOELECTRONIC MATERIAL SCREENING
Broadly speaking, embodiments of the present techniques provide a method and apparatus to quickly and cost effectively screen (5100) a large number of semiconductor materials that may be used for optoelectronic devices. Advantageously, the present techniques use photoluminescence efficiency, PLQE, measurements (S102) and time- resolved photoluminescence, TRPL, measurements (S102) of a sample of a semiconductor material to extract (S104, S106) the parameters needed to screen or evaluate the material. This is advantageous because the measurements can be made using techniques and equipment that is readily accessible to many laboratories and therefore, does not require specialised expertise or equipment that is not readily available in research institutions or industry.
G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
71.
A MACHINE-READABLE MARKER AND IDENTIFICATION METHOD
Broadly speaking, embodiments of the present techniques provide an optically- or machine-readable fiducial marker for use in nanoscale applications and a method for automatic detection of a marker. Advantageously, the fiducial marker of the present techniques has features which make it resistant to the processing steps of electron beam lithography. Furthermore, the fiducial marker is robust when reproduced at nanoscales and has high information density.
G03F 9/00 - Mise en registre ou positionnement d'originaux, de masques, de trames, de feuilles photographiques, de surfaces texturées, p.ex. automatique
Disclosed herein include methods and compositions for culture medias for in vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
Articles comprising a surface or porous substrate and having on said surface or porous substrate a coating comprising microfibrillated cellulose or nanocellulose, methods of applying a coating comprising microfibrillated cellulose or nanocellulose to a surface or porous substrate, compositions comprising microfibrillated cellulose or nanocellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating, and improving filtration efficiency and preparing an antimicrobial surface and/or antiviral surface coating.
UNITED KINGDOM RESEARCH AND INNOVATION (Royaume‑Uni)
AHREN LP, ACTING BY ITS GENERAL PARTNER AHREN INNOVATION CAPITAL GUERNSEY (GP) LIMITED (Royaume‑Uni)
Inventeur(s)
Mcewan, William Alexander
Mukadam, Aamir Shehab
Miller, Lauren Virginia Clare
Tuck, Benjamin James
Keeling, Sophie Elizabeth
Smith, Annabel Emily
Winter, Gregory Paul
James, Leo C.
Abrégé
The invention provides a ligand comprising a first binding moiety which binds to tau assemblies, and a second binding moiety which is bound by TRIM21 for use in the treatment of neurodegenerative disease in the cytoplasm of a neuronal cell, wherein the ligand is administered extracellularly.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
76.
HIGHLY SENSITIVE BIOMOLECULE DETECTION AND QUANTIFICATION
The present invention is directed to methods and devices capable of target analyte separation and analysis, in particular highly sensitive separation and detection and free-solution analyte detection assays.
An apparatus for characterising a biomolecule is provided. The apparatus comprising a sample inlet channel configured to introduce a sample fluid including the biomolecule to the apparatus; an auxiliary inlet channel configured to introduce an auxiliary fluid to the apparatus; a distribution channel in fluid communication with the sample inlet channel and the auxiliary inlet channel; wherein the distribution channel is adapted to generate a distribution of biomolecules; a measurement module configured to detect a signature profile of the biomolecule to obtain a measured dataset of the detected biomolecule; a storage location configured to store and maintain a stored dataset comprising a plurality of parameters that are associated with the measured dataset obtained from the measurement module; and an analysis module configured to receive the stored dataset from the storage location and correlate the stored dataset with the measured dataset from the measurement module to provide a correlation value, wherein the analysis module is further configured to use the correlation value to determine at least two characteristics of the biomolecule simultaneously using Bayesian analysis. A method for characterising a biomolecule is also provided.
G01N 33/558 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
78.
METHOD AND APPARATUS FOR MEASURING PHASE TRANSITION CHARACTERISTICS OF MACROMOLECULES
A method measuring the phase transition characteristics of a macromolecule, the method comprising: generating a stream of micro-droplets comprising at least one constituent, of which one constituent comprises the macromolecule, varying the conditions in the micro-droplets; and measuring the relative concentrations of the constituents of, and the phases of the macromolecule present in, the micro-droplets.
in vitroin vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
This invention relates to a method for codon optimising a target nucleic acid sequence for expression in a host cell. The invention also relates to codon optimised nucleic acids for improved expression in a host cell, and to vectors and host cells comprising codon optimised nucleic acids.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
Articles comprising a surface and having on said surface a coating comprising microfibrillated cellulose, methods of applying a coating comprising microfibrillated cellulose to a surface, compositions comprising microfibrillated cellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating.
The invention relates to methods and compositions to boost immune responses to both infection and vaccination against and infection. In particular, the present invention is aimed at providing a method to boost immune responses to both infection with an infectious agent and vaccination against an infection with an infectious agent. It is also aimed at providing a treatment of infectious disease and vaccine adjuvant for the prevention of infection with an infectious agent.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4045 - Indole-alkylamines; Leurs amides, p.ex. sérotonine, mélatonine
A61K 31/4406 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 3, p.ex. zimeldine
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A method for the detection or prognosis of cancer and/or metastasis is provided. Tumour samples may be used to determine the presence of a mutation within the sodium leak channel (NALCN). A risk score of cancer and/or metastasis can be determined based on if the mutation causes a reduction in the pore size of NALCN. A computational model, a composition, and a kit are also provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
There is provided a system for the production of ammonia, the system comprising: a reservoir for liquid ammonia or water; a first vessel configured to receive gaseous nitrogen and hydrogen feedstocks, the first vessel comprising an ammonia synthesis catalyst and a first material for storing ammonia, a second vessel adjacent and in direct thermal communication with the first vessel, the second vessel comprising a second material for storing ammonia or water, and being in fluid communication with the reservoir for liquid ammonia or water; a third vessel comprising a third material for storing ammonia and comprising an outlet for recovering ammonia; wherein the system has at least two operating modes, wherein: (i) in a first operating mode for retaining ammonia synthesised on the catalyst the first vessel is not in fluid communication with the third vessel, and (ii) in a second operating mode the first vessel is in fluid communication with the third vessel for passing ammonia to the third material.
Various methods of additive layer manufacturing, and objects obtainable by such manufacturing, are disclosed. In particular, there is provided a method of additive layer manufacturing comprising depositing a layer of a material on a surface, and controlling the deposition to vary a material property of the material within the layer. There is also provided a method of additive layer manufacturing comprising depositing at least one layer of material on a sacrificial layer, the layer of material having a thickness of 400 microns or less, wherein the sacrificial layer is located on a base surface.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p.ex. modélisation par dépôt de fil en fusion [FDM]
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
The present invention relates to a process of making an adsorbent body, wherein the process comprises the steps of: (a) contacting adsorbent material with an initial mixture to form a solvated adsorbent mixture in a first solvent; (b) removing the first solvent and removing at least some of the first solvent from the solvated adsorbent mixture in the first solvent to form an initial adsorbent body; (c) contacting the initial adsorbent body with a second solvent to form a reduced-binder adsorbent body in a second solvent; and (d) solvent-drying the reduced-binder adsorbent body to form the adsorbent body. The invention further provides an adsorbent body, and the use of said adsorbent body in gas storage.
B01D 15/02 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solides; Appareillages pour ces procédés par des adsorbants en mouvement
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
1-6 1-6 alkyl groups, -L- is a linker and -B is a non-covalent binding group, such that the bifunctional molecule non-covalently binds to the target nucleic acid molecule, and allowing the bifunctional molecule to cleave the target nucleic acid molecule bound thereto. The invention also provides a method of identifying a secondary or tertiary structure within a target nucleic acid, as well as a bifunctional molecule and a bifunctional molecule for use in a method of treatment.
The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (F.S.P. CNIO) (Espagne)
Inventeur(s)
Macintyre, Geoffrey John
Markowetz, Florian
Drews, Ruben Matthias
Hernando Fuster, Barbara
Abrégé
A method of characterising a DNA sample obtained from a tumour, the method including the steps of: (a) obtaining a tumour copy number profile for the sample, (b) quantifying a set of copy number features of the copy number profile, and (c) determining exposure to one or more signatures of chromosomal instability based on the quantified features. A copy number feature is a metric that characterises a copy number event in a copy number profile. The set of features does not comprise the absolute copy number of segments in the copy number profile. The signatures of chromosomal instability have been obtained by quantifying the set of copy number features in a plurality of tumour samples, and identifying one or more mutational signatures likely to result in the copy number profiles of the plurality of tumour samples. Methods of characterising types of chromosomal instability present in samples, providing a prognosis, identifying a drug target, or identifying a therapy for a subject are also described.
The present invention relates to the field of cancer progression. The invention provides in vivo methods for preventing or inhibiting the migration of cancer cells away from the site of a tumour or a resected tumour, thus inhibiting invasion and metastasis, by contacting all or part of the tumour or resected tumour, or all or part of the vicinity of the tumour, with an agent which impedes the migration and/or proliferation of cancer cells, such as a cross-linking agent.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p.ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/132 - Amines, p.ex. amantadine ayant plusieurs groupes amino, p.ex. spermidine, putrescine
FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NACIONAL DE (Espagne)
Inventeur(s)
Macintyre, Geoffrey John
Markowetz, Florian
Drews, Ruben Matthias
Hernando Fuster, Bárbara
Abrégé
A method of characterising a DNA sample obtained from a tumour, the method including the steps of: (a) obtaining a tumour copy number profile for the sample, (b) quantifying a set of copy number features of the copy number profile, and (c) determining exposure to one or more signatures of chromosomal instability based on the quantified features. A copy number feature is a metric that characterises a copy number event in a copy number profile. The set of features does not comprise the absolute copy number of segments in the copy number profile. The signatures of chromosomal instability have been obtained by quantifying the set of copy number features in a plurality of tumour samples, and identifying one or more mutational signatures likely to result in the copy number profiles of the plurality of tumour samples. Methods of characterising types of chromosomal instability present in samples, providing a prognosis, identifying a drug target, or identifying a therapy for a subject are also described.
An organic light emitting device, comprising an anode; a cathode; and an emissive layer between the anode and the cathode, wherein the emissive layer comprises a first material which is an organic semiconductor compound and a second material which is a different organic semiconductor compound that has a spin doublet ground state; and wherein a lowest spin singlet excitation energy of the first material and a lowest spin triplet excitation energy of the first material are greater than a lowest spin doublet excitation energy of the second material; a method of fabricating an organic light emitting device, comprising: forming an emissive layer between an anode and a cathode, wherein the emissive layer comprises a first material which is an organic semiconductor compound and a second material which is a different organic semiconductor compound that has a spin doublet ground state; and wherein a lowest spin singlet excitation energy of the first material and a lowest spin triplet excitation energy of the first material are greater than a lowest spin doublet excitation energy of the second material; and a method of operating the device by applying a voltage across the device, such that spin singlet excited states and spin triplet excited states are formed for the first material, wherein energy is transferred from spin singlet excited states in the first material and spin triplet excited states in the first material to form spin doublet excited states in the second material, wherein the second material emits fluorescent light when transitioning from a spin doublet excited state to a ground state.
H01L 51/50 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives spécialement adaptés pour l'émission de lumière, p.ex. diodes émettrices de lumière organiques (OLED) ou dispositifs émetteurs de lumière à base de polymères (PLED)
H01L 51/00 - Dispositifs à l'état solide qui utilisent des matériaux organiques comme partie active, ou qui utilisent comme partie active une combinaison de matériaux organiques et d'autres matériaux; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de tels dispositifs ou de leurs parties constitutives
95.
Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes
The Board of Trustees of the University of Illinois (USA)
Cambridge Enterprise Limited (Royaume‑Uni)
Inventeur(s)
Aksimentiev, Aleksei
Keyser, Ulrich F.
Abrégé
The present invention provides compositions and methods for transferring phospholipids and other molecules between the leaflets of a cell membrane. The compositions comprise at least one nucleic acid or compound having a hydrophilic region, where the composition is able to form a nanostructure that forms a toroidal pore in a lipid membrane. The nucleic acid or hydrophilic region-containing compound further contains an attached molecule capable of inserting the nanostructure into the lipid membrane. The invention also provides methods for scrambling lipids and other molecules in a cell membrane, which can be used to alter the function of a selected cell or to facilitate the death of the cell. The scrambling activity of synthetic scramblases described herein outperforms previously known enzymatically active DNA nanostructures and naturally occurring scramblases, in some cases by several orders of magnitude.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
96.
METHOD FOR ELECTROCHEMICALLY ETCHING A SEMICONDUCTOR STRUCTURE
A method for etching a semiconductor structure (110) is provided, the semiconductor structure comprising a sub-surface quantum structure (30) of a first III-V semiconductor material, beneath a surface layer (31) of a second III-V semiconductor material having a charge carrier density of less than 5 × 1017 cm-3. The sub-surface quantum structure may comprise, for example, a quantum well, or a quantum wire, or a quantum dot. The method comprises the steps of exposing the surface layer to an electrolyte (130), and applying a potential difference between the first III-V semiconductor material and the electrolyte, to electrochemically etch the sub-surface quantum structure (30) to form a plurality of nanostructures, while the surface layer (31) is not etched. A semiconductor structure, uses thereof, and devices incorporating such semiconductor structures are further provided.
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 33/02 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs
H01L 33/06 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure à effet quantique ou un superréseau, p.ex. jonction tunnel au sein de la région électroluminescente, p.ex. structure de confinement quantique ou barrière tunnel
H01L 33/10 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les corps semi-conducteurs ayant une structure réfléchissante, p.ex. réflecteur de Bragg en semi-conducteur
H01L 33/32 - Matériaux de la région électroluminescente contenant uniquement des éléments du groupe III et du groupe V de la classification périodique contenant de l'azote
The invention relates to methods for nucleic acid characterisation. In particular, the method of the invention relates to methods for characterising target nucleic acids in a sample.
A method for porosifying a III-nitride material in a semiconductor structure is provided, the semiconductor structure comprising a sub-surface structure of a first III-nitride material, having a charge carrier density greater than 5×1017 cm−3, beneath a surface layer of a second III-nitride material, having a charge carrier density of between 1×1014 cm−3 and 1×1017 cm−3. The method comprises the steps of exposing the surface layer to an electrolyte, and applying a potential difference between the first III-nitride material and the electrolyte, so that the sub-surface structure is porosified by electrochemical etching, while the surface layer is not porosified. A semiconductor structure and uses thereof are further provided.
The invention relates to a lithium sulfur cell, a method of preparing a lithium sulfur cell, and a battery comprising the lithium sulfur cell. The lithium sulfur cell comprises a working electrode comprising a film comprising stacked layers of a metallic phase transition metal dichalcogenide of formula (I): LiaMX2 where a is from 0.0 to 2.0, X is selected from S, Se and Te, and M is a transition metal, such as Ti, Hf, V, Nb, Ta, Mo, W, Tc, Re, Pd or Pt. The method of preparing a lithium sulfur cell comprises: exfoliating a transition metal dichalcogenide to provide a metallic phase, transition metal dichalcogenide of formula (I); assembling a working electrode comprising a film comprising stacked layers of the metallic phase transition metal dichalcogenide and sulfur or a lithium (poly)sulfide; and assembling a lithium sulfur cell comprising the working electrode, a counter electrode, and an electrolyte.
H01M 4/136 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
Liquid dressing compositions liquid for veterinary use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a non-human animal subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents in a veterinary setting.
